Literature

Manual extraction of PFAS in drinking water in compliance with ISO 21675

Written by Biotage | Dec 6, 2025 6:15:01 AM

Introduction


Per- and polyfluorinated alkyl substances (PFAS) have been used abundantly since their inception in the twentieth century and have become a closely monitored class of compounds within environmental testing. This application note outlines a procedure for those seeking to follow ISO 21675. The data presented was generated using a Biotage® VacMaster™ vacuum manifold with a PFAS free Large Volume Extraction (LVE) kit in conjunction with EVOLUTE® PFAS SPE cartridges and a TurboVap® LV system.

 

Equipment and materials used


Biotage

  • Biotage® VacMaster™ 20 Sample Processing Station With 15 mm Rack, p/n 121-2015ML, fitted with polypropylene (PFAS free) stopcocks (p/n 121-0009-PP)
  • Biotage® VacMaster™ LVE Kit (PFAS) for 1, 3, 6 mL SPE Cartridges (p/n 121-2190)
  • EVOLUTE® PFAS 500 mg/6 mL SPE Cartridges, p/n 614-0050-CP
  • EVOLUTE® PFAS 150 mg/6 mL SPE Cartridges, p/n 614-0015-CP
  • TurboVap® LV Automated Solvent Evaporation System, p/n 415000
  • TurboVap® LV Multi Rack (48 Positions, 10–20 mm Tubes), p/n 414964

 

Wellington Laboratories

  • ISO 21675:2019 Labelled Stock Solution, 1.2 mL, p/n ISO 21675-LSS
  • ISO 21675:2019 Native Stock Solution, 1.2 mL, p/n ISO 21675-NSS

 

Agilent

  • InfinityLab PFC Delay Cartridge, 4.6 x 30 mm, p/n 5062-8100
  • ZORBAX RRHD Eclipse Plus C18, 95 Å, 2.1 x 50 mm, 1.8 µm, p/n 959757-902

 

Sigma-Aldrich

  • Ammonium Acetate, ACS Reagent Grade ≥ 97%, p/n 238074-25G
  • Acetic Acid, Glacial, Reagent Plus® , ≥ 99% p/n A6283


Honeywell

  • Water, ACS Certified, HPLC Grade, p/n AH365-4
  • Methanol, Burdick & Jackson™ , LC-MS Grade, p/n LC230-4


VWR

  • 15 mL Polypropylene Centrifuge Tubes with Caps, p/n 21008-670
  • 250 mL Polypropylene Wide Mouth Bottles, p/n 414004-125


Analytes


Table 1. Listing of Target Analytes and Internal Standards.

Target Analyte

Acronym

CAS

Perfluoro-n-butanesulfonic acid

PFBS

375-73-5

Perfluoro-n-hexanesulfonic acid

PFHxS

355-46-4

Perfluoro-n-heptanesulfonic acid

PFHpS

375-92-8

Perfluoro-n-octanesulfonic acid

PFOS

1763-23-1

Perfluoro-n-decanesulfonic acid

PFDS

335-77-3

Perfluorooctanesulfonamide

FOSA

754-91-6

N-methyl perfluoroctanesulfonamide

N-MeFOSA

31506-32-8

N-ethyl perfluorooctanesulfonamide

N-EtFOSA

4151-50-2

N-methyl perfluorooctanesulfonamidoacetic acid

N-MeFOSAA

2355-31-9

N-ethyl perfluorooctanesulfonamidoacetic acid

N-EtFOSAA

2991-50-6

6:2 Fluorotelomer sulfonic acid

6:2 FTSA

27619-97-2

8:2 Fluorotelomer sulfonic acid

8:2 FTSA

39108-34-4

9-Chlorohexadecafluoro-3-oxanonane-1-sulfonic acid

9Cl-PF3ONS

73606-19-6

Perfluoro-n-butanoic acid

PFBA

375-22-4

Perfluoro-n-pentanoic acid

PFPeA

2706-90-3

Perfluoro-n-hexanoic acid

PFHxA

307-24-4

Perfluoro-n-heptanoic acid

PFHpA

375-85-9

Perfluoro-n-octanoic acid

PFOA

335-67-1

Perfluoro-n-nonanoic acid

PFNA

375-95-1

Perfluoro-n-decanoic acid

PFDA

335-76-2

Perfluoro-n-undecanoic acid

PFUnDA

2058-94-8

Perfluoro-n-dodecanoic acid

PFDoDA

307-55-1

Perfluoro-n-tridecanoic acid

PFTrDA

72629-94-8

Perfluoro-n-tetradecanoic acid

PFTeDA

376-06-7

Perfluoro-n-hexadecanoic acid

PFHxDA

67905-19-5

Perfluoro-n-octadecanoic acid

PFOcDA

16517-11-6

8:2 Fluorotelomer unsaturated carboxylic acid

8:2 FTUCA

70887-84-2

8:2 Polyfluoroalkyl phosphate diester

8:2 diPAP

678-41-1

Hexafluoropropylene oxide dimer acid

HFPO-DA

13252-13-6

4,8-Dioxa-3H-perfluorononanoic acid

DONA

919005-14-4

Target Analyte

Acronym                                        CAS

Internal Standard

 

Sodium perfluoro-1-[2,3,4-13C3]butanesulfonate

13C3-PFBS

Sodium perfluoro-1-[1,2,3-13C3]hexanesulfonate

13C3-PFHxS

Sodium perfluoro-1-[1,2,3-18O2]hexanesulfonate

18O2-PFHxS

Sodium perfluoro-1-[1,2,3,4-13C4]octanesulfonate

13C4-PFOS

Sodium perfluoro-1-[1,2,3,4-13C8]octanesulfonate

13C8-PFOS

Perfluoro-1-[13C8]octanesulfonamide

13C8-FOSA

N-methyl-d3-perfluoro-1-octanesulfonamide

d3-N-MeFOSA

N-ethyl-d5-perfluoro-1-octanesulfonamide

d5-N-EtFOSA

N-deuteriomethylperfluoro-1-octanesulfonamidoacetic acid

d3-N-MeFOSAA

N-deuterioethylperfluoro-1-octanesulfonamidoacetic acid

d5-N-EtFOSAA

Sodium 1H,1H,2H,2H-perfluoro-1-[1,2-13C2]-octane sulfonate

13C2-6:2 FTSA

Sodium 1H,1H,2H,2H-perfluoro-1-[1,2-13C2]-decane sulfonate

13C2-8:2 FTSA

Perfluoro-n-[1,2,3,4-13C4]butanoic acid

13C4-PFBA

Perfluoro-n-[1,2,3,4,5-13C5]pentanoic acid

13C5-PFPeA

Perfluoro-n-[1,2-13C2]hexanoic acid

13C2-PFHxA

Perfluoro-n-[1,2-13C5]hexanoic acid

13C5-PFHxA

Perfluoro-n-[1,2,3,4-13C4]heptanoic acid

13C4-PFHpA

Perfluoro-[1,2-13C4]octanoic acid

13C4-PFOA

Perfluoro-[1,2-13C8]octanoic acid

13C8-PFOA

Perfluoro-n-[13C5]nonanoic acid

13C5-PFNA

Perfluoro-n-[13C9]nonanoic acid

13C9-PFNA

Perfluoro-n-[1,2-13C2]decanoic acid

13C2-PFDA

Perfluoro-n-[1,2-13C6]decanoic acid

13C6-PFDA

Perfluoro-n-[1,2,3,4,5,6,7-13C2]undecanoic acid

13C2-PFUnDA

Perfluoro-n-[1,2,3,4,5,6,7-13C7]undecanoic acid

13C7-PFUnDA

Perfluoro-n-[1,2-13C2]dodecanoic acid

13C2-PFDoDA

Perfluoro-n-[1,2-13C2]tetradecanoic acid

13C2-PFTeDA

Perfluoro-n-[1,2-13C2]hexadecanoic acid

13C2-PFHxDA

2H-Perfluoro-[1,2-13C2]-2-decenoic acid

13C2-8:2 FTUCA

Sodium bis(1H,1H,2H,2H-[1,2-13C2]perfluorodecyl)-

phosphate

 

13C4-8:2 diPAP

Tetrafluoro-2-heptafluoropropoxy-13C3-propanoic acid

13C3-HFPO-DA

 

Solution preparation


Ammonia/Methanol solution

  1. Add 400 μL of NH4OH for every 100 mL of methanol to a clean beaker.
  2. Agitate to homogenize.
  3. Prepare new solution daily.


Acetate buffer

  1. Measure out 499.5 mL of reagent water in a clean beaker.
  2. Add 0.193 g of NH4Ac.
  3. Sonicate the solution for 5 minutes until the salt is fully dissolved.
  4. Add 570 μL of glacial acetic acid.
  5. Agitate to homogenize the solution.


Working spiking solution

  1. Dilute 100 μL of the native stock solution with 900 μL of methanol to achieve a 10 ppt solution.
     

Summary of SPE method


SPE cartridge format


EVOLUTE® PFAS 500 mg/6 mL or EVOLUTE® PFAS 150 mg/6 mL


Sample pre-treatment


Adjust the pH of each sample to 3 using glacial acetic acid. Add targets and internal standards.


Conditioning


Condition each cartridge with 0.1 % NH4OH in methanol (10 mL) followed by methanol (10 mL).


Equilibration


Equilibrate each cartridge with reagent water (10 mL).


Sample loading


Load sample at a flow rate of 5 mL/min.


Wash


Rinse the sample container with acetate buffer solution (10 mL) and load onto the cartridge. Repeat using reagent water (10 mL).


Dry


Dry the cartridge for 5 minutes at a flow rate of 5 mL/min.


Elution


Rinse the sample container with methanol (5 mL) and use to elute the analytes from the cartridge at a flow rate of 2 mL/min. Repeat using 0.1 % NH4OH in methanol (5 mL).


Post extraction


Concentrate the extract to a volume of 1 mL and analyse.

Sample preparation procedure

  1. Clean all parts of the Biotage® VacMaster™ system per the procedure given in Appendix A.
  2. Set up and fill new sample containers with of water; 250–500 mL are typical for this method.
  3. Add glacial acetic acid to each of the sample containers to reduce the pH to 3 (approximately 100 μL for 250 mL sample volumes and 200 μL for 500 mL sample volumes).
  4. Verify the pH of the sample is 3 using pH paper. To reduce the possibility of contamination, a duplicate volume was collected and adjusted to the appropriate pH and the same volume of acid was added to the sample container.
  5. Prepare for the determination of the initial sample volume by either marking the level of the sample on the container or by weighing the sample container.
  6. Add 20 μL of the undiluted Labelled Stock Solution to each of the sample containers. If desired, fortify a sample using target analytes: the addition of 125 μL or 37.5 μL of the native stock solution will yield either 50 ppt or 15 ppt concentrations respectively, while the addition of 50 μL of the working spiking solution will yield a 2 ppt concentration. If the mixes used were different than the ones outlined in this note, adjust the concentration or spiking amounts as needed.
  7. Load the desired EVOLUTE® PFAS cartridges onto the Biotage® VacMaster™. Seal any unused positions using VacMaster™ Port Sealing Plugs (p/n 121-0005)
  8. Rinse each cartridge with 10 mL of 0.1 % NH4OH in methanol and apply vacuum at 10 mL/min to pull it to waste. Do not allow the sorbent to go dry.
  9. Rinse each cartridge with 10 mL of methanol and apply vacuum at 10 mL/min to pull it to waste. Do not allow the sorbent to go dry.
  10. Rinse each cartridge with 10 mL of reagent water and apply vacuum at 10 mL/min to send it to waste. Do not allow the water level to drop below the top of the packing.
  11. Using the Biotage® VacMaster™ LVE Kit, place one end of the cleaned tubing into the bottom of each of the sample
    containers, and secure in position using the clips provided.
  12.  Load the samples onto the cartridges using a flow rate of 5 mL/min.
  13. Once the sample has been fully loaded, rinse the sample containers using 10 mL of acetate buffer solution, swirl to ensure the full rinsing of the container, and load the aliquot onto the cartridge at a rate of 5 mL/min.
  14.  Rinse the sample containers using 10 mL of reagent water, swirl to ensure the full rinsing of the container, and load the aliquot onto the cartridge at a rate of 5 mL/min.
  15. Dry the cartridge for 5 minutes at a rate of 5 mL/min.
  16. Load 15 mL centrifuge tubes into the rack corresponding to each of the cartridge positions and load into the Biotage® VacMaster™.
  17. Rinse each sample container using 5 mL of methanol and swirl to ensure the full rinsing of the container. Load the aliquot through the appropriate cartridge and collect at a dropwise rate.
  18. Rinse each sample container using 5 mL of 0.1% NH4OH in methanol and swirl to ensure the full rinsing of the container. Load the aliquot through the appropriate cartridge and collect at a dropwise rate.
  19. Determine the initial sample volume by either using a graduated cylinder and filling the sample container to the original mark or by taking an additional weight of the container.
  20. Transfer the centrifuge tubes to the TurboVap® LV system and concentrate the samples to just under 1 mL using nitrogen according to the parameters in Table 2.
  21. Bring the final extract to 1 mL and transfer to an autosampler vial.
  22. Load the extract onto a calibrated LC-MS/MS system and process using the conditions given in the below sections.

TurboVap® LV concentration protocol


Bath Temp: 60 ˚C
Evaporation Mode: Method (Ramp Gradient)
Manifold Setup: 48 positions
Rack Row Height: 120 mm*
Step 1: 1.5 L/min for 20 min
Step 2: 3.0 L/min for 15 min
Step 3: 3.5 L/min for 45 min

*The nozzle position was adjusted such that it was as far to the right as possible to give the user a clear view of the vortex within the tube.

LC-MS/MS conditions


Agilent 1290 Infinity II LC System


» 1290 Infinity II Multicartridge Thermostat, G7116B
» 1290 Infinity II Multisampler, G7167B
» 1290 Infinity II High Speed Pump, G7120A
» InfinityLab PFC-free HPLC Conversion Kit, 5004-0006


Cartridges


» InfinityLab PFC Delay Cartridge, 4.6 x 30 mm, p/n 5062-8100
» ZORBAX RRHD Eclipse Plus C18, 95 Å, 2.1 x 50 mm, 1.8 µm, p/n 959757-902


Mobile phases


» A: 20 mM Ammonium Acetate in Water
» B: Methanol

Time (min)

%A

%B

0.50

95.00

5.00

3.00

60.00

40.00

16.00

20.00

80.00

18.00

20.00

80.00

20.00

5.00

95.00

20.50

0.00

100.00

25.00

0.00

100.00

26.00

5.00

95.00

 

» Flow Rate: 0.2 mL/min
» Injection Volume: 5 μL
» Cartridge Temperature: 50 ˚C


Agilent 6470 MS/MS, G6470B


» Gas Temperature: 230 ˚C
» Gas Flow: 4 L/min
» Nebulizer: 20 psi
» Sheath Gas Temperature: 375 ˚C
» Sheath Gas Flow: 12 L/min
» Capillary Voltage (Positive): 3500 V
» Capillary Voltage (Negative): 3500 V
» Nozzle Voltage (Positive): 500 V
» Nozzle Voltage (Negative): 0 V

For a complete listing of MRM Transitions, see Appendix B

Results


System calibration


For the work being done here, a total of six points were used in the calibration covering a range of 0.2–20 ppt in the sample. The lowest three points were below the calculated MRL. The curve was forced through zero and achieved excellent linearity across the calibration range.

Figure 1. Calibration curves for PFBS and PFHxS. Calibration curves for the remaining target analytes in Table 1 are shown in Appendix C.

Determination of the Minimum Reporting Level (MRL) and Detection Limits (DL)


A target MRL of 2 ng/L was selected and at least seven replicate laboratory fortified blanks (LFBs) were created and run at that concentration. Figure 2 below illustrates the results of this test for both the 150 mg and 500 mg cartridges using 250 mL sample volumes; all compounds were recovered within 15% of the spiked amount and had less than 10% CV.

Figure 2. MRL and DL Recoveries. Those compounds with an asterisk were used in salt form.

The data for individual compounds is shown in Appendix D.

 

Demonstration of low system background


An investigation into the background of the complete process was done in three steps. The first step was to run blank injections of methanol on the analytical system (system blank). The second step was to load centrifuge tubes containing a similar volume of methanol as would result from the extraction process onto the evaporation system, allowing them to concentrate and then run on the analytical system (evaporation blank). The third and final step was to create a full Laboratory Reagent Blank (LRB), extract and concentrate it, and run it on the analytical system. By separating the process into three steps it becomes easier to determine what, if any, contribution to the overall background each of the steps has. The result of these tests are given in Appendix E and selected data are shown below in Figures 3–5.

 
Figure 3. Contribution of the TurboVap® LV to the PFAS Background. Those compounds with an asterisk were used in salt form.


Figure 4. PFAS Background for full LRB using EVOLUTE® PFAS 500 mg/6 mL cartridges. Those compounds with an asterisk were used in salt form.


Figure 5. PFAS Background for full LRB using EVOLUTE® PFAS 150 mg/6 mL cartridges. Those compounds with an asterisk were used in salt form.

For those results which were generated using only the analytical system, all target analytes were N.D. (unable to be separated from the noise in the baseline) and so were not listed out in the previous tables.
 
When examining the data resulting for both the TurboVap® LV and the full LRB tests (which includes the Biotage® VacMaster™ manifold, PFAS Free Large Volume Loading Kit, and the EVOLUTE® cartridges as well as the TurboVap® LV) there are clear indications of the presence of a PFAS background. However, even at the highest concentrations detected, all levels are much lower than the 1/3 MRL limit indicating that the background is acceptable and will not interfere with future sample runs.


Initial Demonstration of Precision and Accuracy (IDP, IDA)


To determine the precision and accuracy of the sample preparation process, four LFB samples were prepared at concentrations of 15 ppt. The data is given in Appendix F and illustrated in Figures 6 and 7.

Figure 6. Initial Demonstration of Accuracy (15 ng/L, n=4). Those compounds with an asterisk were used in salt form.


Figure 7. Initial Demonstration of Precision (15 ng/L, n=4). Those compounds with an asterisk were used in salt form.


The results show that the average recovery for each target analyte was within 15% of the nominal value and that the coefficient of variation (CV) for each analyte fell under 10% on average.

 

Examination of system carryover


To simulate an influent sample, four LFB samples were created with concentrations which were above the range of the calibration curve. These samples were extracted, and the clean-up procedure given in Appendix A was run three times. To ensure that the system background was adequately reduced, a set of four LRB samples were extracted immediately afterwards and analysed. The LRB data is presented in Appendix G and illustrated in Figure 8.

 

Figure 8. Results of carryover study following four, 50 ng/L LFB samples using EVOLUTE® PFAS 500 mg/6 mL cartridges. Those compounds with an asterisk were used in salt form.
The graph shown in Figure 8 shows a clear indication that the cleaning procedure in Appendix A was successful in reducing the background of PFAS compounds to below the 1/3 MRL limit. For further reductions in the background, additional cleaning steps could be employed.
 

Conclusion


With the scrutiny being given to the presence of PFAS compounds in the environment, it is essential to find reliable products which can meet the requirements of ISO 21675. This application note has shown that the Biotage® VacMaster™ vacuum manifold with PFAS free accessories, EVOLUTE® PFAS SPE cartridges and the TurboVap® LV can be used to easily meet and exceed the demands of the method.

Ordering information

Part Number

Description

Qty

121-2015ML

Biotage® VacMaster™ 20 Sample Processing Station With 15 mm Rack

1

121-2190

Biotage® VacMaster™ LVE Kit (PFAS) for 1, 3, 6 mL SPE Cartridges

1

121-0009-PP

Polypropylene (PFAS) Stopcocks

10

614-0050-CP

EVOLUTE® PFAS 500 mg/6 mL cartridges

30

614-0015-CP

EVOLUTE® PFAS 150 mg/6 mL cartridges

30

415000

TurboVap® LV Automated Solvent Evaporation System

1

414964

TurboVap® LV Multi Rack (48 Positions, 10–20 mm Tubes)

1

 

Appendix A


Biotage® VacMaster™ cleaning procedure

For the best results, it is recommended that this procedure be completed before the use of the Biotage® VacMaster™ each day and at the end of each extraction prior to proceeding with the next set of samples.

  1. Ensure that a cartridge and cartridge adapter is installed onto each VacMaster™ position slated to be cleaned.
  2. Fill a clean beaker with 50 mL of methanol and place no more than four of the LVE Kit lines into the beaker.
  3. Apply vacuum to the manifold and pull the methanol through the positions into the waste container.
  4. Remove the cartridge and discard.
  5. Using methanol in a squeeze bottle, clean the exterior of the LVE Kit’s lines, the cartridge adapters, the stopcock, and the metal cannula. Discard all rinsate.
  6. Repeat this up to three times for all positions which require cleaning.

Note: In situations where the previous sample was highly concentrated, the above cleaning procedure may need to be repeated multiple times. If there is concern regarding potential carryover contamination regardless of the cleaning procedure, a laboratory reagent blank should be run in that position to ensure its cleanliness.


Appendix B


MRM transitions

 

MRM Transitions for Agilent 6470 MS/MS.

Cpd Name

ISTD?

Prec Ion

MS1 Res

Prod Ion

MS2 Res

Frag (V)

CE (V)

Cell Acc (V)

Ret Time (min)

Ret Window

Polarity

6:2FTS

No

427

Unit/Enh (6490)

406.8

Unit/Enh (6490)

125

24

5

13.3

1.37

Negative

6:2FTS

No

427

Unit/Enh (6490)

80.9

Unit/Enh (6490)

125

40

5

13.3

1.37

Negative

8:2 diPAP

No

989

Unit/Enh (6490)

543

Unit/Enh (6490)

100

20

5

22.15

2.33

Negative

8:2 diPAP

No

989

Unit/Enh (6490)

97

Unit/Enh (6490)

100

20

5

22.15

2.33

Negative

8:2 FTS

No

527

Unit/Enh (6490)

506.8

Unit/Enh (6490)

170

28

5

16.2

1.64

Negative

8:2 FTS

No

527

Unit/Enh (6490)

80.9

Unit/Enh (6490)

170

40

5

16.2

1.64

Negative

8:2 FTUCA

No

457

Unit/Enh (6490)

393

Unit/Enh (6490)

100

28

5

15.25

1.56

Negative

8:2 FTUCA

No

457

Unit/Enh (6490)

343

Unit/Enh (6490)

100

28

5

15.25

1.56

Negative

9Cl-PF3ONS

No

530.9

Unit/Enh (6490)

350.9

Unit/Enh (6490)

145

28

5

15.7

1.6

Negative

9Cl-PF3ONS

No

530.9

Unit/Enh (6490)

83

Unit/Enh (6490)

145

32

5

15.7

1.6

Negative

ADONA

No

377

Unit/Enh (6490)

250.9

Unit/Enh (6490)

80

12

5

11.8

1.23

Negative

ADONA

No

377

Unit/Enh (6490)

85

Unit/Enh (6490)

80

36

5

11.8

1.23

Negative

C2-6:2FTS

No

429

Unit/Enh (6490)

81

Unit/Enh (6490)

125

24

5

13.3

1.37

Negative

C2-8:2FTS

No

529

Unit/Enh (6490)

81

Unit/Enh (6490)

170

28

5

16.2

1.64

Negative

C2-8:2FTUCA

No

459

Unit/Enh (6490)

394

Unit/Enh (6490)

100

28

5

15.25

1.56

Negative

C2-PFDoA

No

615

Unit/Enh (6490)

570

Unit/Enh (6490)

79

5

5

18.2

1.84

Negative

C2-PFHxDA

No

815

Unit/Enh (6490)

770

Unit/Enh (6490)

100

20

5

21.5

2.19

Negative

C2-PFTeDA

No

715

Unit/Enh (6490)

670

Unit/Enh (6490)

79

5

5

19.9

2.03

Negative

C3-HFPO-DA

No

287

Unit/Enh (6490)

169

Unit/Enh (6490)

155

4

5

10.3

1

Negative

C3-PFBS

No

302

Unit/Enh (6490)

80

Unit/Enh (6490)

100

45

5

7.9

1.61

Negative

C3-PFHxS

No

402

Unit/Enh (6490)

80

Unit/Enh (6490)

100

49

5

11.7

1.5

Negative

C4-8:2diPAP

No

993

Unit/Enh (6490)

545

Unit/Enh (6490)

100

20

5

22.15

2.23

Negative

C4-PFBA

No

217

Unit/Enh (6490)

172

Unit/Enh (6490)

60

8

5

5.1

1.45

Negative

C4-PFHpA

No

367

Unit/Enh (6490)

322

Unit/Enh (6490)

72

0

5

11.6

1.2

Negative

C5-PFHxA

No

318

Unit/Enh (6490)

273

Unit/Enh (6490)

70

8

5

9.7

1.14

Negative

C5-PFPeA

No

268

Unit/Enh (6490)

223

Unit/Enh (6490)

60

20

5

7.4

1.55

Negative

C6-PFDA

No

519

Unit/Enh (6490)

474

Unit/Enh (6490)

81

4

5

16.2

1.65

Negative

C7-PFUdA

No

570

Unit/Enh (6490)

525

Unit/Enh (6490)

100

20

5

17.2

1.75

Negative

C8-FOSA

No

506

Unit/Enh (6490)

78

Unit/Enh (6490)

150

20

5

16.8

1.71

Negative

C8-PFOA

No

421

Unit/Enh (6490)

376

Unit/Enh (6490)

80

8

5

13.4

1.38

Negative

C8-PFOS

No

507

Unit/Enh (6490)

80

Unit/Enh (6490)

100

50

5

15

1.53

Negative

C9-PFNA

No

472

Unit/Enh (6490)

427

Unit/Enh (6490)

66

4

5

14.9

1.52

Negative

d3-N-MeFOSA

No

515

Unit/Enh (6490)

169

Unit/Enh (6490)

100

28

5

18.8

1.91

Negative

d3-N-MeFOSAA

No

573

Unit/Enh (6490)

419

Unit/Enh (6490)

100

20

5

16.7

1.7

Negative

d5-N-EtFOSA

No

531

Unit/Enh (6490)

169

Unit/Enh (6490)

100

32

5

19.6

1.2

Negative

d5-N-EtFOSAA

No

589

Unit/Enh (6490)

419

Unit/Enh (6490)

100

20

5

17.25

1.75

Negative

FOSA

No

498

Unit/Enh (6490)

169

Unit/Enh (6490)

100

38

5

16.8

1.71

Negative

FOSA

No

498

Unit/Enh (6490)

78

Unit/Enh (6490)

150

38

5

16.8

1.71

Negative

Cpd Name

ISTD?

Prec Ion

MS1 Res

Prod Ion

MS2 Res

Frag (V)

CE (V)

Cell Acc (V)

Ret Time (min)

Ret Window

Polarity

HFPO-DA-CO2

No

285

Unit/Enh (6490)

184.9

Unit/Enh (6490)

155

16

5

10.3

1.5

Negative

HFPO-DA-CO2

No

285

Unit/Enh (6490)

168.9

Unit/Enh (6490)

155

4

5

10.3

1.5

Negative

N-EtFOSA

No

526

Unit/Enh (6490)

219

Unit/Enh (6490)

100

32

5

19.6

1.99

Negative

N-EtFOSA

No

526

Unit/Enh (6490)

169

Unit/Enh (6490)

100

28

5

19.6

1.99

Negative

N-EtFOSAA

No

584

Unit/Enh (6490)

526

Unit/Enh (6490)

100

20

5

17.3

1.75

Negative

N-EtFOSAA

No

584

Unit/Enh (6490)

419

Unit/Enh (6490)

100

20

5

17.3

1.75

Negative

N-MeFOSA

No

512

Unit/Enh (6490)

219

Unit/Enh (6490)

100

28

5

18.8

1.91

Negative

N-MeFOSA

No

512

Unit/Enh (6490)

169

Unit/Enh (6490)

100

28

5

18.8

1.91

Negative

N-MeFOSAA

No

570

Unit/Enh (6490)

512

Unit/Enh (6490)

100

20

5

16.7

1.7

Negative

N-MeFOSAA

No

570

Unit/Enh (6490)

419

Unit/Enh (6490)

100

20

5

16.7

1.7

Negative

PFBA

No

213

Unit/Enh (6490)

168.9

Unit/Enh (6490)

60

8

5

5.1

1.48

Negative

PFBS

No

298.9

Unit/Enh (6490)

98.9

Unit/Enh (6490)

100

29

5

7.9

1.41

Negative

PFBS

No

298.9

Unit/Enh (6490)

80

Unit/Enh (6490)

100

45

5

7.9

1.41

Negative

PFDA

No

513

Unit/Enh (6490)

469

Unit/Enh (6490)

81

4

5

16.2

1.65

Negative

PFDA

No

513

Unit/Enh (6490)

218.7

Unit/Enh (6490)

100

16

5

16.2

1.65

Negative

PFDoA

No

613

Unit/Enh (6490)

569

Unit/Enh (6490)

79

5

5

18.2

1.84

Negative

PFDoA

No

613

Unit/Enh (6490)

268.7

Unit/Enh (6490)

100

20

5

18.2

1.84

Negative

PFDS

No

599

Unit/Enh (6490)

99

Unit/Enh (6490)

100

40

5

17.15

1.75

Negative

PFDS

No

599

Unit/Enh (6490)

80

Unit/Enh (6490)

100

40

5

17.15

1.75

Negative

PFHpA

No

362.9

Unit/Enh (6490)

319

Unit/Enh (6490)

72

0

5

11.6

1.2

Negative

PFHpA

No

362.9

Unit/Enh (6490)

169

Unit/Enh (6490)

72

12

5

11.6

1.2

Negative

PFHpS

No

448.9

Unit/Enh (6490)

98.7

Unit/Enh (6490)

100

44

5

13.5

1.39

Negative

PFHpS

No

448.9

Unit/Enh (6490)

79.7

Unit/Enh (6490)

100

52

5

13.5

1.39

Negative

PFHxA

No

313

Unit/Enh (6490)

268.9

Unit/Enh (6490)

70

8

5

9.7

1.12

Negative

PFHxA

No

313

Unit/Enh (6490)

119

Unit/Enh (6490)

70

18

5

9.7

1.12

Negative

PFHxDA

No

813

Unit/Enh (6490)

769

Unit/Enh (6490)

79

5

5

21.5

2.19

Negative

PFHxDA

No

813

Unit/Enh (6490)

369

Unit/Enh (6490)

100

20

5

21.5

2.19

Negative

PFHxS

No

398.9

Unit/Enh (6490)

99

Unit/Enh (6490)

100

45

5

11.7

1.5

Negative

PFHxS

No

398.9

Unit/Enh (6490)

80

Unit/Enh (6490)

100

49

5

11.7

1.5

Negative

PFNA

No

463

Unit/Enh (6490)

419

Unit/Enh (6490)

66

4

5

14.9

1.52

Negative

PFNA

No

463

Unit/Enh (6490)

219

Unit/Enh (6490)

66

17

5

14.9

1.52

Negative

PFOA

No

413

Unit/Enh (6490)

369

Unit/Enh (6490)

69

4

5

13.4

1.38

Negative

PFOA

No

413

Unit/Enh (6490)

169

Unit/Enh (6490)

69

12

5

13.4

1.38

Negative

PFOcDA

No

913

Unit/Enh (6490)

869

Unit/Enh (6490)

79

5

5

22.35

2.25

Negative

PFOcDA

No

913

Unit/Enh (6490)

369

Unit/Enh (6490)

100

20

5

22.35

2.25

Negative

PFOS

No

498.9

Unit/Enh (6490)

99

Unit/Enh (6490)

100

50

5

15

1.53

Negative

PFOS

No

498.9

Unit/Enh (6490)

80

Unit/Enh (6490)

100

50

5

15

1.53

Negative

PFPeA

No

263

Unit/Enh (6490)

218.9

Unit/Enh (6490)

60

8

5

7.4

1.77

Negative

PFTeDA

No

713

Unit/Enh (6490)

669

Unit/Enh (6490)

79

5

5

19.9

2.03

Negative

PFTeDA

No

713

Unit/Enh (6490)

369

Unit/Enh (6490)

100

20

5

19.9

2.03

Negative

PFTrDA

No

663

Unit/Enh (6490)

619

Unit/Enh (6490)

79

5

5

19

1.93

Negative

PFTrDA

No

663

Unit/Enh (6490)

269

Unit/Enh (6490)

100

20

5

19

1.93

Negative

PFUnA

No

563

Unit/Enh (6490)

519

Unit/Enh (6490)

73

5

5

17.2

1.75

Negative

PFUnA

No

563

Unit/Enh (6490)

269

Unit/Enh (6490)

100

20

5

17.2

1.75

Negative

 

Appendix C


Calibration curves

Figure 9. Calibration curves for the target analytes in Table 1, covering a concentration range of 0.2-20 ppt.

 

Appendix D


MRL and DL data


MRL and DL Recoveries for EVOLUTE® PFAS 500 mg/6 mL cartridges.

 

Conc. (ng/L)

1

(ng/L)

2

(ng/L)

3

(ng/L)

4

(ng/L)

5

(ng/L)

6

(ng/L)

7

(ng/L)

x̅ (ng/L)

x̅ (%)

s (ng/L)

CV

(%)

DL

(ng/L)

PFBA*

1.77

1.67

1.71

1.67

1.68

1.81

1.60

1.80

1.71

96

0.08

4.43

0.24

PFPeA

2.00

1.85

1.83

1.92

1.97

1.88

1.75

1.91

1.87

94

0.07

3.81

0.22

PFBS

2.00

1.73

1.90

1.82

1.70

1.73

1.65

1.95

1.78

89

0.11

6.12

0.34

PFHxA

2.00

1.80

1.92

1.89

1.80

1.98

1.75

1.92

1.87

93

0.08

4.50

0.26

HFPO-DA

2.00

1.80

1.58

1.48

1.83

1.89

1.73

1.69

1.71

86

0.14

8.39

0.45

PFHpA

2.00

1.96

2.06

2.04

1.94

2.01

1.80

2.08

1.99

99

0.09

4.75

0.30

PFHxS*

1.90

1.85

1.78

1.77

1.70

1.82

1.73

1.77

1.77

94

0.05

2.84

0.16

DONA*

1.89

1.76

1.85

1.79

1.85

1.79

1.64

1.80

1.78

94

0.07

3.98

0.22

PFHpS*

1.91

1.90

1.90

1.86

1.65

1.92

1.51

1.73

1.78

93

0.16

8.79

0.49

6:2 FTSA*

1.90

1.80

1.87

1.88

1.86

1.87

1.68

1.86

1.83

96

0.07

4.02

0.23

PFOA

2.00

1.80

1.86

1.93

1.91

1.94

1.67

1.94

1.86

93

0.10

5.34

0.31

PFOS*

1.92

1.96

1.89

1.79

1.89

1.92

1.69

1.89

1.86

97

0.09

4.98

0.29

PFNA

2.00

1.88

1.92

1.95

1.90

1.94

1.79

2.07

1.92

96

0.08

4.30

0.26

8:2 FTUCA

2.00

1.93

1.87

1.90

1.95

2.05

1.89

1.97

1.94

97

0.06

3.15

0.19

PFDA

2.00

1.87

1.89

1.87

1.83

2.01

1.79

2.01

1.89

95

0.09

4.55

0.27

9Cl-PF3ONS*

1.87

1.75

1.71

1.76

1.73

1.74

1.53

1.75

1.71

92

0.08

4.72

0.25

8:2 FTSA*

1.92

1.73

1.83

1.72

1.77

1.90

1.70

2.10

1.82

95

0.14

7.93

0.45

N-MeFOSAA

2.00

1.83

1.90

1.92

1.81

1.94

1.76

2.02

1.88

94

0.09

4.80

0.28

FOSA

2.00

2.09

2.06

2.12

1.97

2.16

1.98

2.28

2.09

105

0.11

5.17

0.34

PFDS

2.00

2.10

2.06

1.95

2.14

1.70

1.64

1.93

1.93

97

0.19

9.98

0.61

PFUnDA

2.00

1.89

1.91

1.90

1.81

1.88

1.75

1.94

1.87

93

0.07

3.51

0.21

N-EtFOSAA

2.00

2.04

1.86

2.00

1.98

1.99

1.73

1.94

1.93

97

0.11

5.44

0.33

PFDoDA

2.00

1.85

1.96

1.96

1.81

2.00

1.75

1.96

1.90

95

0.10

5.04

0.30

PFTrDA

2.00

1.79

1.85

1.87

1.98

2.02

1.75

2.04

1.90

95

0.11

5.89

0.35

N-MeFOSA

2.00

2.17

2.14

2.01

1.94

2.36

2.04

2.34

2.14

107

0.16

7.50

0.51

N-EtFOSA

2.00

1.99

1.97

2.06

2.11

2.09

1.99

2.03

2.03

102

0.05

2.59

0.17

PFTeDA

2.00

1.79

1.82

1.91

1.85

1.89

1.83

1.86

1.85

93

0.04

2.12

0.12

PFHxDA

2.00

1.95

1.94

1.93

1.99

1.95

1.89

2.07

1.96

98

0.06

2.81

0.17

8:2 diPAP*

1.96

1.79

1.85

2.00

1.90

1.78

1.78

2.16

1.90

97

0.14

7.51

0.45

PFOcDA

2.00

1.71

1.88

2.07

1.60

1.71

1.64

1.75

1.77

88

0.16

9.18

0.51

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 
MRL and DL Recoveries for EVOLUTE® PFAS 150 mg/6 mL cartridges.

 

Conc. (ng/L)

1

(ng/L)

2

(ng/L)

3

(ng/L)

4

(ng/L)

5

(ng/L)

6

(ng/L)

7

(ng/L)

8

(ng/L)

x̅ (ng/L)

x̅ (%)

s (ng/L)

CV

(%)

DL

(ng/L)

PFBA*

1.77

1.88

1.83

1.87

1.94

1.83

1.86

1.79

1.83

1.85

104

0.05

2.56

0.14

PFPeA

2.00

1.96

1.92

1.96

2.05

1.97

1.93

1.86

1.96

1.95

98

0.05

2.79

0.16

PFBS

2.00

1.87

1.76

1.84

1.73

1.77

1.81

1.73

1.75

1.78

89

0.05

2.83

0.15

PFHxA

2.00

2.09

2.00

2.04

2.10

2.03

2.09

1.98

2.08

2.05

103

0.05

2.20

0.14

HFPO-DA

2.00

1.97

1.92

1.82

1.92

1.89

2.14

2.16

2.17

2.00

100

0.14

6.92

0.41

PFHpA

2.00

2.08

1.96

1.98

1.91

2.04

1.95

2.01

2.01

1.99

100

0.06

2.76

0.17

PFHxS*

1.90

1.75

1.83

1.80

1.85

1.66

1.74

1.77

1.74

1.77

93

0.06

3.34

0.18

DONA*

1.89

1.98

1.90

1.96

1.96

1.93

1.84

1.96

1.90

1.93

102

0.05

2.35

0.14

PFHpS*

1.91

1.77

1.78

1.85

1.79

1.64

1.66

1.69

1.64

1.73

91

0.08

4.69

0.24

6:2 FTSA*

1.90

1.91

1.84

1.97

1.92

2.05

2.06

2.01

2.11

1.98

104

0.09

4.58

0.27

PFOA

2.00

1.96

1.99

2.01

2.08

1.97

2.05

1.91

1.97

1.99

100

0.05

2.59

0.15

PFOS*

1.92

2.00

1.89

1.93

2.01

1.95

1.95

1.98

1.96

1.96

102

0.04

1.99

0.12

PFNA

2.00

2.08

1.94

2.02

2.01

2.04

2.08

2.11

2.02

2.03

102

0.05

2.59

0.16

8:2 FTUCA

2.00

1.93

1.92

1.97

1.95

1.94

1.98

1.95

1.98

1.95

98

0.02

1.17

0.07

PFDA

2.00

1.99

1.89

1.96

1.99

1.91

2.03

2.07

2.04

1.98

99

0.06

3.12

0.19

9Cl-PF3ONS*

1.87

1.96

1.92

1.91

1.97

1.86

1.84

1.83

1.92

1.90

102

0.05

2.68

0.15

8:2 FTSA*

1.92

1.92

1.93

2.01

1.99

1.90

1.84

1.88

1.97

1.93

101

0.06

3.06

0.18

N-MeFOSAA

2.00

1.85

1.84

1.84

1.85

1.91

2.00

2.03

2.06

1.92

96

0.09

4.87

0.28

FOSA

2.00

1.96

2.00

1.99

2.12

2.16

2.20

2.16

2.15

2.09

105

0.09

4.49

0.28

PFDS

2.00

1.92

2.08

1.81

2.04

2.01

1.93

2.04

1.90

1.97

98

0.09

4.61

0.27

PFUnDA

2.00

2.09

1.97

1.93

1.95

1.89

1.97

1.95

1.98

1.97

98

0.06

2.94

0.17

N-EtFOSAA

2.00

1.86

1.93

1.98

1.98

1.96

2.16

2.10

2.02

2.00

100

0.09

4.68

0.28

PFDoDA

2.00

2.08

1.91

2.02

2.05

2.02

2.03

2.04

2.04

2.02

101

0.05

2.52

0.15

PFTrDA

2.00

2.01

1.93

1.85

1.99

1.94

2.06

1.98

1.99

1.97

98

0.06

3.21

0.19

N-MeFOSA

2.00

2.01

2.13

2.03

1.93

2.13

2.18

1.96

2.02

2.05

102

0.09

4.37

0.27

N-EtFOSA

2.00

1.86

2.10

1.88

2.27

1.91

2.16

2.05

2.13

2.04

102

0.15

7.30

0.45

PFTeDA

2.00

2.07

2.03

1.91

2.03

1.98

1.99

2.13

2.05

2.02

101

0.06

3.17

0.19

PFHxDA

2.00

2.01

1.91

1.81

2.08

2.05

1.95

2.02

2.03

1.98

99

0.09

4.43

0.26

8:2 diPAP*

1.96

2.05

2.03

2.03

2.06

2.05

2.11

1.78

1.94

2.01

103

0.10

5.12

0.31

PFOcDA

2.00

1.99

2.32

2.39

2.06

2.07

2.11

2.00

2.02

2.12

106

0.15

7.13

0.45

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 

Appendix E


PFAS background study


Results of PFAS Background Study for EVOLUTE® PFAS 500 mg/6 mL cartridges (recoveries in ng/L).

TurboVap® LV

Laboratory Reagent Blanks

Replicate

1

2

3

4

5

6

7

8

1

2

3

4

PFBA*

0.00

0.00

0.00

0.00

0.00

0.10

0.05

0.04

0.09

0.06

0.06

0.06

PFPeA

0.02

0.03

0.03

0.03

0.03

0.06

0.02

0.03

0.04

0.04

0.02

0.04

PFBS

0.01

0.00

0.00

0.00

0.01

0.00

0.01

0.01

0.00

0.00

0.00

0.06

PFHxA

0.01

0.02

0.00

0.01

0.00

0.02

0.01

0.02

0.02

0.02

0.02

0.02

HFPO-DA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHpA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHxS*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.00

0.01

0.01

0.01

DONA*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.00

PFHpS*

0.00

0.02

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

6:2 FTSA*

0.02

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.05

0.06

0.07

0.07

PFOA

0.02

0.00

0.00

0.00

0.03

0.00

0.01

0.00

0.00

0.00

0.00

0.00

PFOS*

0.00

0.00

0.00

0.00

0.03

0.00

0.00

0.02

0.01

0.02

0.01

0.01

PFNA

0.00

0.00

0.00

0.01

0.00

0.00

0.00

0.00

0.02

0.00

0.01

0.00

8:2 FTUCA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.01

0.00

0.00

PFDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.02

0.00

0.00

0.00

0.00

9Cl-PF3ONS*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.01

0.00

0.00

0.00

8:2 FTSA*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

N-MeFOSAA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

FOSA

0.00

0.01

0.00

0.00

0.00

0.01

0.00

0.01

0.00

0.00

0.00

0.01

PFDS

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFUnDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

N-EtFOSAA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFDoDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFTrDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

N-MeFOSA

0.02

0.00

0.00

0.00

0.00

0.01

0.00

0.00

0.00

0.07

0.07

0.00

N-EtFOSA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFTeDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHxDA

0.10

0.04

0.00

0.00

0.08

0.12

0.07

0.11

0.00

0.00

0.00

0.00

8:2 diPAP*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFOcDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 
Results of PFAS Background Study for EVOLUTE® PFAS 150 mg/6 mL cartridges (recoveries in ng/L).

TurboVap® LV

Laboratory Reagent Blanks

Replicate

1

2

3

4

1

2

3

4

PFBA*

0.06

0.02

0.01

0.00

0.11

0.09

0.09

0.10

PFPeA

0.03

0.03

0.03

0.02

0.05

0.06

0.04

0.04

PFBS

0.01

0.01

0.00

0.00

0.00

0.01

0.01

0.01

PFHxA

0.02

0.02

0.01

0.00

0.03

0.03

0.02

0.02

HFPO-DA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHpA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHxS*

0.01

0.01

0.00

0.00

0.01

0.01

0.01

0.01

DONA*

0.01

0.00

0.00

0.00

0.01

0.01

0.01

0.00

PFHpS*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

6:2 FTSA*

0.01

0.00

0.00

0.00

0.03

0.03

0.04

0.02

PFOA

0.00

0.02

0.03

0.00

0.00

0.00

0.05

0.00

PFOS*

0.00

0.00

0.01

0.01

0.00

0.00

0.00

0.00

PFNA

0.00

0.01

0.00

0.00

0.00

0.00

0.01

0.00

8:2 FTUCA

0.01

0.00

0.00

0.01

0.01

0.01

0.00

0.00

PFDA

0.00

0.02

0.00

0.00

0.00

0.00

0.00

0.02

9Cl-PF3ONS*

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.01

8:2 FTSA*

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

N-MeFOSAA

0.00

0.00

0.00

0.00

0.02

0.00

0.03

0.02

FOSA

0.00

0.01

0.00

0.00

0.01

0.00

0.01

0.01

PFDS

0.00

0.00

0.01

0.00

0.00

0.00

0.00

0.00

PFUnDA

0.00

0.00

0.00

0.00

0.02

0.00

0.00

0.00

N-EtFOSAA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFDoDA

0.00

0.06

0.00

0.00

0.00

0.00

0.00

0.00

PFTrDA

0.00

0.05

0.00

0.00

0.00

0.00

0.00

0.00

N-MeFOSA

0.00

0.00

0.00

0.02

0.00

0.00

0.00

0.05

N-EtFOSA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFTeDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

PFHxDA

0.07

0.08

0.08

0.06

0.08

0.08

0.12

0.07

8:2 diPAP*

0.00

0.01

0.00

0.00

0.00

0.00

0.00

0.00

PFOcDA

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 

Appendix F


IDP and IDA data


Results of IDP and IDA for EVOLUTE® PFAS 500 mg/6 mL cartridges (15 ng/L, n=4).

Replicate

1 (%)

2 (%)

3 (%)

4 (%)

x̅ (%)

s (%)

CV (%)

PFBA*

93.97

93.52

97.66

94.56

94.93

1.87

1.97

PFPeA

91.10

99.84

99.34

92.16

95.61

4.62

4.83

PFBS

88.73

88.20

91.76

86.48

88.79

2.20

2.47

PFHxA

94.83

95.12

99.13

95.85

96.23

1.98

2.06

HFPO-DA

88.53

89.13

99.41

92.60

92.42

4.99

5.40

PFHpA

104.38

106.43

104.54

106.18

105.38

1.07

1.02

PFHxS*

95.20

99.75

101.57

95.96

98.12

3.04

3.10

DONA*

102.56

111.10

108.04

107.16

107.22

3.53

3.30

PFHpS*

89.31

87.18

98.22

79.57

88.57

7.67

8.66

6:2 FTSA*

96.43

102.56

100.83

101.53

100.34

2.70

2.69

PFOA

94.28

94.77

96.59

92.79

94.61

1.56

1.65

PFOS*

91.58

93.17

98.48

89.66

93.22

3.79

4.06

PFNA

93.76

98.27

100.96

96.89

97.47

2.99

3.07

8:2 FTUCA

95.54

99.14

95.99

95.27

96.49

1.79

1.86

PFDA

96.19

91.59

101.20

100.51

97.38

4.45

4.57

9Cl-PF3ONS*

94.73

93.29

104.59

90.45

95.76

6.15

6.42

8:2 FTSA*

87.94

97.85

90.95

98.83

93.89

5.30

5.64

N-MeFOSAA

102.65

101.19

100.15

94.75

99.68

3.44

3.45

FOSA

106.21

102.48

110.06

100.99

104.94

4.06

3.87

PFDS

96.50

102.88

108.47

98.56

101.60

5.29

5.21

PFUnDA

88.89

85.05

87.96

90.74

88.16

2.37

2.69

N-EtFOSAA

97.35

101.86

99.64

94.11

98.24

3.31

3.37

PFDoDA

96.65

99.00

102.74

98.79

99.30

2.53

2.55

PFTrDA

104.99

91.30

96.05

98.68

97.76

5.71

5.84

N-MeFOSA

103.38

114.84

108.73

99.89

106.71

6.53

6.12

N-EtFOSA

103.01

111.52

107.20

103.88

106.40

3.86

3.63

PFTeDA

92.57

95.31

96.88

94.10

94.71

1.83

1.93

PFHxDA

90.55

89.61

92.53

94.89

91.89

2.34

2.54

8:2 diPAP*

92.57

99.94

98.71

96.49

96.93

3.24

3.34

PFOcDA

104.86

101.06

106.48

97.58

102.49

3.99

3.89

Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 
Results of IDP and IDA for EVOLUTE® PFAS 150 mg/6 mL cartridges (15 ng/L, n=4).

Replicate

1 (%)

2 (%)

3 (%)

4 (%)

x̅ (%)

s (%)

CV (%)

PFBA*

102.37

101.69

101.80

103.26

102.28

0.72

0.70

PFPeA

101.89

102.16

101.32

100.30

101.42

0.82

0.81

PFBS

99.30

102.15

99.56

102.63

100.91

1.72

1.71

PFHxA

100.58

103.25

99.56

100.27

100.92

1.61

1.60

HFPO-DA

96.01

95.99

99.76

93.05

96.20

2.75

2.86

PFHpA

102.78

102.88

102.64

102.10

102.60

0.35

0.34

PFHxS*

97.07

98.52

98.87

97.40

97.96

0.86

0.88

DONA*

102.74

104.41

102.11

103.16

103.11

0.97

0.94

PFHpS*

91.57

92.08

90.92

93.18

91.94

0.95

1.04

6:2 FTSA*

99.40

99.12

104.89

102.46

101.47

2.74

2.70

PFOA

104.83

105.70

104.59

106.65

105.44

0.94

0.89

PFOS*

101.18

103.31

101.24

102.55

102.07

1.04

1.02

PFNA

102.52

103.28

101.34

101.57

102.18

0.90

0.88

8:2 FTUCA

98.30

100.36

102.72

101.33

100.68

1.86

1.84

PFDA

102.85

104.63

101.29

103.65

103.10

1.41

1.37

9Cl-PF3ONS*

106.62

106.89

104.87

103.91

105.57

1.42

1.35

8:2 FTSA*

100.77

102.18

104.64

100.22

101.95

1.97

1.93

N-MeFOSAA

103.10

103.15

103.09

105.71

103.76

1.30

1.25

FOSA

103.88

101.39

103.04

101.42

102.43

1.23

1.20

PFDS

105.46

102.18

103.54

106.38

104.39

1.89

1.81

PFUnDA

98.55

97.67

97.27

98.90

98.10

0.76

0.77

N-EtFOSAA

101.28

102.59

103.05

103.63

102.64

1.00

0.97

PFDoDA

105.74

103.29

103.54

105.36

104.48

1.25

1.19

PFTrDA

103.97

103.44

104.62

100.69

103.18

1.73

1.67

N-MeFOSA

95.71

101.62

105.13

103.48

101.48

4.11

4.05

N-EtFOSA

100.27

105.18

104.36

98.73

102.14

3.12

3.06

PFTeDA

102.22

102.79

101.51

101.23

101.94

0.71

0.69

PFHxDA

98.11

100.02

100.23

99.48

99.46

0.95

0.96

8:2 diPAP*

102.35

99.99

98.16

101.37

100.47

1.82

1.81

PFOcDA

106.66

107.30

101.64

101.58

104.30

3.11

2.99

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.
 

Appendix G


Carryover data


Results of carryover study following four, 50 ng/L LFB samples using EVOLUTE® PFAS 500 mg/6 mL cartridges.

Replicate

1

(ng/L)

2

(ng/L)

3

(ng/L)

4

(ng/L)

x̅ (ng/L)

PFBA*

0.11

0.09

0.09

0.09

0.09

PFPeA

0.04

0.04

0.04

0.04

0.04

PFBS

0.02

0.01

0.02

0.01

0.02

PFHxA

0.02

0.02

0.03

0.03

0.03

HFPO-DA

0.00

0.00

0.00

0.00

0.00

PFHpA

0.00

0.00

0.00

0.00

0.00

PFHxS*

0.02

0.00

0.02

0.01

0.01

DONA*

0.00

0.01

0.01

0.00

0.00

PFHpS*

0.00

0.00

0.00

0.00

0.00

6:2 FTSA*

0.04

0.04

0.04

0.04

0.04

PFOA

0.09

0.04

0.07

0.00

0.05

PFOS*

0.04

0.03

0.04

0.04

0.04

PFNA

0.00

0.00

0.00

0.00

0.00

8:2 FTUCA

0.02

0.01

0.03

0.04

0.03

PFDA

0.02

0.02

0.02

0.02

0.02

9Cl-PF3ONS*

0.01

0.00

0.02

0.01

0.01

8:2 FTSA*

0.00

0.00

0.00

0.00

0.00

N-MeFOSAA

0.08

0.12

0.14

0.11

0.11

FOSA

0.03

0.02

0.02

0.03

0.03

PFDS

0.03

0.00

0.00

0.00

0.01

PFUnDA

0.00

0.00

0.03

0.01

0.01

N-EtFOSAA

0.07

0.09

0.08

0.10

0.09

PFDoDA

0.00

0.00

0.00

0.00

0.00

PFTrDA

0.00

0.00

0.03

0.00

0.01

N-MeFOSA

0.21

0.21

0.17

0.27

0.22

N-EtFOSA

0.16

0.17

0.15

0.18

0.17

PFTeDA

0.00

0.00

0.00

0.00

0.00

PFHxDA

0.07

0.12

0.13

0.07

0.10

8:2 diPAP*

0.00

0.00

0.05

0.08

0.03

PFOcDA

0.00

0.00

0.00

0.00

0.00

*Analytes were used in salt form and calculated concentrations were corrected to compensate where needed.

 

Literature number: AN967
View full post